Active Ingredient History
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Lymphoma, B-Cell, Marginal Zone (approved 2021)
Lymphoma, Follicular (approved 2021)
Colorectal Neoplasms (Phase 1)
Esophageal Neoplasms (Phase 1)
Hodgkin Disease (Phase 2)
Intestinal Neoplasms (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2/Phase 3)
Lymphoma, Follicular (Phase 2/Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 2/Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1)
Pancreatic Neoplasms (Phase 1)
Polycythemia Vera (Phase 1)
Primary Myelofibrosis (Phase 1)
Rectal Neoplasms (Phase 1)
Stomach Neoplasms (Phase 1)
Waldenstrom Macroglobulinemia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue